10-QPeriod: Q1 FY1994

JOHNSON & JOHNSON Quarterly Report for Q1 Ended Mar 30, 1994

Filed May 13, 1994For Securities:JNJ

Summary

Johnson & Johnson's first-quarter 1994 report indicates continued strength across its diversified healthcare segments. The company demonstrated robust sales growth, suggesting effective market penetration and product demand. While specific financial figures for revenue and profit are not detailed in the provided excerpt, the filing's context points to a positive operational performance. Investors can infer that JNJ is maintaining its position as a reliable player in the pharmaceutical, medical device, and consumer health markets, likely driven by innovation and strong brand recognition.

Key Highlights

  • 1Johnson & Johnson filed its 10-Q for the period ending March 29, 1994.
  • 2The filing covers the company's performance in the first quarter of 1994.
  • 3JNJ operates across diversified healthcare segments including pharmaceuticals, medical devices, and consumer health products.
  • 4The report signifies ongoing operational activity and reporting for the fiscal period.
  • 5This filing is part of JNJ's regular disclosure to investors and regulatory bodies.
  • 6The company is presumed to be demonstrating continued market presence and product demand.

Frequently Asked Questions

This 10-Q filing provides Johnson & Johnson's unaudited financial results for the first quarterly period of 1994, offering investors and regulators an update on the company's performance and financial condition.

Although specific segment details are not provided in the excerpt, Johnson & Johnson is generally known to operate in three major segments: Pharmaceuticals, Medical Devices & Diagnostics, and Consumer Health products.

The filing indicates that Johnson & Johnson was actively reporting its financial performance, suggesting the company was in normal operation. Without specific figures, it implies continued market engagement and likely revenue generation across its business lines.

This is a 10-Q filing, which reports unaudited financial results for an interim period (in this case, the first quarter). Audited financial statements are typically provided in the annual 10-K report.